"None of us who've been there need to speak on it," Samuel said. Johns legacy will be felt for generations to come, living on through the scientific progress made under his leadership and the programs he championed that expanded access to medications for people around the world, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences. 6 among the world's 50 best . A chemist by training, he turned Gilead Sciences into a leading, and lucrative, innovator with single-pill treatments for H.I.V. Press question mark to learn the rest of the keyboard shortcuts. (650) 522-5643. It is with great sadness that the company has learned of the passing of Dr. Martin, whose scientific vision and leadership helped transform the lives of millions of patients and shape Gilead into the company that it is today. Martin, the CEO of Foster City, Calif.-based Gilead Sciences from 1996 to 2016, didnt seek to dominate the room or inspire legions with a charismatic personality. "By 2011, Gilead accounted for almost half of the U.S. market for HIV drug production, according to the New York Times. According to the New York Times, the Justice Department could seek billions of dollars in royalties for Gilead's previous sales of the drug, which brings in about $3 billion each year for the company. [2], Martin was divorced. John Harvey Clark December 9, 2022 (94 years old) View obituary. Gilead, died Wednesday, September 15, 2021 at his residence. While the company did see revenue windfalls, it proved to be temporary because the drugs were so effective, they created a virtual cure for the disease and the patient pool dwindled. into a manageable disease and who popularized another drug that cures. Five years later, shortly after Martin announced he was stepping down from his role as executive chairman, the Trump administration sued the company, alleging Gilead infringed upon patents owned by the U.S. Department of Health and Human Services in order to develop Truvada as an HIV-preventative drug. made by his company, Gilead Sciences, in the Bay Area. That meant I was often first in the office. and hepatitis C. Johns legacy, Daniel ODay, the companys chief executive, said in a statement, will be felt for generations to come, living on through the scientific progress made under his leadership and the programs he championed that expanded access to medications for people around the world.. [6], Martin was director of antiviral chemistry at Bristol-Myers Squibb from 1984 to 1990. One Saturday morning on the day of Gileads annual company picnic, a beach event at Half Moon Bay, I stopped by the office in Foster City first to get a little work done. Martin is credited as the editor.) His death, in a hospital, was confirmed by Gilead Sciences, based in Foster City, Calif., where he was chief executive from 1996 to 2016 and executive chairman from 2016 until he retired two years later. John likely already knew the answer or had a better answer than what you might muster up. All Rights Reserved. Sign up to be notified of new comments on this topic. November 5, 2022 (87 years old) View obituary. February 7, 1985 - February 26, 2023. The pill combined two of the most prescribed AIDS medications at the time Gilead's Truvada and Bristol-Myers Squibb's Sustiva and was set at a price of $1,100 a month. May 7, 1951-March 30, 2021 This close working relationship extended beyond researchers and clinicians to the patient community. Comedian and radio show host D.L. I was just getting to know him better. The companys biggest advance on the H.I.V. Martin joined Gilead in 1990. Roche and Exelixis are reporting a second flop out of a trio of Phase III trials designed to test a combination of their PD-L1 drug and tyrosine kinase inhibitor. Five years later, shortly after Martin announced he was stepping down from his role as executive chairman, the Trump administration sued the company, alleging Gilead infringed upon patents owned by the U.S. Department of Health and Human Services in order to develop Truvada as an HIV-preventative drug. Gilead was founded 30 years ago and now the biotech start-up has become a leading US pharmaceutical company behind flu and HIV treatments, Tamiflu and Atripla. In 1978, he joined Syntex Laboratories, which was headquartered in Palo Alto. Community Calendar Alfredo Naj Domingos prostate cancer was spreading. John C. Martin in 2006 with a bottle of Truvada, a groundbreaking treatment for H.I.V. In the industry, however, Martin was widely loved. PR MediaRelease But the small talk of those huddled around him inevitably turned, and as most casual conversations almost always did with John, to the excitement of the work. John Martin Obituary - John Martin Death : Gilead CEO Dies: Cause Of Death: Funeral- Gilead CEO, John Martin has died aged 70, on March, 2021, with loved ones left in total devastation. All rights reserved. John Wayne Martin, 73, of Onvil Rd., Mt. "It funded a number of scientists' projects in the developing world," Lange said. Some of his accolades include the American Chemical Society's Horace S. Isbell Award, which acknowledges significant research in carbohydrate chemistry and biochemistry; the International Society for Antiviral Research's Gertrude B. Elion Award for Scientific Excellence; and a Lifetime Achievement Award for Public Service from the Institute of Human Virology at the University of Maryland School. John R. Martin John R. Martin, age 84, of Winterhaven, CA, passed away Dec. 22, 2022 in Yuma, AZ. "We developed the drug; we invented it.". John Martin Obituary With heavy hearts, we announce the death of John Martin (Fountain Inn, South Carolina), born in Columbia, South Carolina, who passed away on February 4, 2023. Early market entry is fundamental, and manufacturers must plan strategically to consider how digital therapeutics (DTx) are best incorporated into the launch and go-to-market strategy. "You really have to care about the poor and the fact that the bulk of HIV are in poor developing world countries," Samuel said. The nonprofit is based in Palo Alto. 19 Results. Martin is credited as the editor.) Under Martin's leadership, Gilead also developed the first anti-influenza pill, Tamiflu, which was licensed to Hoffmann-La Roche, a Swiss health care company; and Truvada, which was approved by the FDA to treat HIV in 2004 and for HIV infection prevention in 2012. Im fortunate to have seen Martin work at close range, and consider him a mentor. While Hughley is not a patient, hes connected to cancer through his father and sister, and hes also a vocal advocate for equitable health care. Gilead rejected the government's complaint and has maintained that the patents were invalid. {Click link below to read more. "Martin also started a foundation under his name with a mission to improve health care in "socially and economically-disadvantaged settings," according to the foundation's website. Martin first joined Gilead, a biopharmaceutical company based in Foster City, in 1990 as the vice president of its research and development department. Search within r/DeathObituaries. Martin came to work at Gilead in 1990, when it was a startup working on antisense oligonucleotide drug candidates. TownSquare He then worked at Syntex and Bristol Myers as a medicinal chemist leading antiviral drug programs. Both Moffitt Cancer Center and Mayo Clinic in Florida, not too far from Domingos and his family, said he would have to wait between three and a half and four months to get the treatment. In his last major act as CEO, Martin oversaw the acquisition of Kite Pharma and its CAR-T platform to strengthen the companys oncology and cell therapy bona fides. John Martin, the former CEO of Gilead Sciences, has died, the New York Times reports.He was 69. A few days after a meeting on organizational effectiveness, John gave me a copy of Nietzsches Beyond Good and Evil. He explained the dynamics of managers and subordinates and how those in authority are often perceived wrongly in terms of ethics and intention by those who work for them. Martin joined Gilead in 1990. Endpoints News connected with the new chair of the generic industrys Association for Accessible Medicines, Christine Baeder, who is also Tevas COO, via video conference on Friday. John expected that the top researchers and clinicians would personally know the top managers at Gilead. [10], In 2014, Martin led the commercialization of Sovaldi (sofosbuvir) Redwood City Pulse, 2023 Palo Alto Online John Charles Martin was born on May 7, 1951, in Easton, Pa., the son of Tellis Alexander Martin, a chemist for Bristol-Myers, and Janet (Sacks) Martin, who taught chemistry, physics and computer literacy at a prep school in Indiana. Blogs It was this belief that later led to Gilead's launch of tenofovir, trademarked as Viread, which was approved by the U.S. Federal Drug Administration as an anti-HIV treatment in 2001. Pricing and access to medicines were perennial thorny issues at Gilead. [5] He served on the board of trustees of the latter two universities. Martin also started a foundation under his name with a mission to improve health care in "socially and economically-disadvantaged settings," according to the foundation's website. [6], Martin has worked with the Federal government of the United States in a number of capacities. The Palo Alto Police Department confirmed in an email to this news organization that a man in his 60s appeared to have fallen in the area at around 6:30 p.m. And dont come back until the doctor agrees to join us as a medical science liaison, he added. In 2014, Democrat lawmakers asked Martin to justify the company's $84,000 price tag of its hepatitis C drug, Sovaldi, which is equivalent to $1,000 per pill. Advertising Info But his most notable contributions to the company came after he was named CEO in 1996.Of note is the development of Atripla, the first single-tablet regimen for treating HIV, which hit the market in 2006. The Palo Alto Police Department confirmed in an email to this news organization that a man in his 60s appeared to have fallen in the area at around 6:30 p.m. In 2014, Democrat lawmakers asked Martin to justify the company's $84,000 price tag of its hepatitis C drug, Sovaldi, which is equivalent to $1,000 per pill. Framed group photos highlighting Gileads history decorated the walls. "None of us who've been there need to speak on it," Samuel said. While thinking through this strategic pivot, John saw that antiretroviral cocktail therapies were emerging as the most potent weapons yet in the AIDS epidemic. This is not a complete listing of all burials in this cemetery.
Of note is the development of Atripla, the first single-tablet regimen for treating HIV, which hit the market in 2006. Baeder explains below not only whats coming for AAM and its member generic drug companies, but also her thoughts on the Inflation Reduction Act and the new five-year FDA user fee deal. Embarcadero Media Find the obituary of John Wayne Martin (1948 - 2021) from Mount Gilead, NC. "So a single pill once a day is a huge step forward.". Today, its the second highest-valued biopharma company ranking behind only Amgen. "And that's what John did that's what he convinced the board was the right thing to do.". - Click to. John unified Gilead around the easy-to-understand vision of one pill, once a day. It became the north star for the company. However, in April 2014, U.S. House Democrats Henry Waxman, Frank Pallone Jr., and Diana DeGette wrote Martin questioning the $84,000 price for Sovaldi. John C Martin is Deceased at Gilead Sciences Inc. See John C Martin's compensation, career history, education, & memberships. Astolfo E Valenzuela. For more information on Gilead Sciences, please visit the companys website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. John C. Martin, former CEO of Gilead Sciences who helped develop the first once-a-day pill to treat HIV while at the helm of the company, died unexpectedly on March 30 after suffering head injuries from a fall the previous day. John Wayne Martin, 73, of Mt. John C. Martin, former CEO of Gilead Sciences who helped develop the first once-a-day pill to treat HIV while at the helm of the company, died unexpectedly on March 30 after suffering head injuries from a fall the previous day. Sign up for the Peninsula Foodist newsletter. Press J to jump to the feed. He had served in the US Marine Corps and had worked as a Correctional Officer and in Security. 1 His wife, Nora Flor, said she and her sister made calls to at least 30 centers across the US looking for the drug. John would later be seen at the picnic chatting with employees, watching others play volleyball and eating barbecue. Generic drugs are more often than not the unsung heroes in healthcare, generating billions in savings every year and increasing access to vital new medicines as the brand-name versions come off patent. Master Sergeant John Martin Jr. was born, November 20, 1933, in Paia, Maui, Hawaii. Obituary . According to the New York Times, the Justice Department could seek billions of dollars in royalties for Gilead's previous sales of the drug, which brings in about $3 billion each year for the company. Gilead Sciences, Inc. (Nasdaq: GILD) today released the following statement on the death of John C. Martin, PhD, who served as the company's chief executive officer from 1996 to 2016 and as its chairman from 2008 to 2019. The malignant cells permeated his bones, kidney, lungs and liver, and in December, his oncologist told him there was no point in continuing chemotherapy treatment. His death at the age of 69 was flagged by the company he built, though a. "[12], Sofosbuvir is cited as an example of how specialty drugs present both benefits and challenges. "If you missed doses, the HIV virus could mutate and become resistant," said Lange, who continued to work on other projects with Martin after the sale of his company. But the little biotech from Foster City, California, over the course of a decade, reigned supreme as the worlds largest maker of HIV medicines. "You really have to care about the poor and the fact that the bulk of HIV are in poor developing world countries," Samuel said. Uploaded: Mon, Apr 5, 2021, 3:24 pm Martin's death was announced by Gilead, where he served as CEO from 1996 to 2016. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Martin joined Gilead in 1990. He stepped down as CEO in 2016 but maintained a role in the company as executive chairman from 2016 to 2018. In addition to running Gilead, Dr. Martin was president of the International Society for Antiviral Research from 1998 to 2000. My first few months at Gilead were spent traveling the world visiting every top expert HBV clinician to learn about the disease, the current state of treatment and what outcomes would be most meaningful. During his time with Gilead, Martin also expanded access to HIV medication in developing countries. Samuel, who led the company's program to make the company's medicine accessible to poorer countries, credits Martin for that initiative. He didnt focus on selling a future vision of Gilead. To send a flower arrangement or to plant trees in memory of Palo Alto utilities customers could see rate increase of about $17 a month, "None of us who've been there need to speak on it," Samuel said. John began his career at Gilead in 1990, as vice president of Research & Development. Martin also started a foundation under his name with a mission to improve health care in "socially and economically-disadvantaged settings," according to the foundation's website. John handled these issues with aplomb working methodically behind the scenes. New to Endpoints? Former Sarepta CEO Gets $15M From Hedge Fund for Startup Incubator, Q&A on Drug Pricing with Gileads Gregg Alton: Outtakes From the Podcast. Gilead rejected the government's complaint and has maintained that the patents were invalid. "And that's what John did that's what he convinced the board was the right thing to do. Can California's power grid handle a 15-fold increase in electric cars? As chief executive officer from 1996 through 2016, he steered the company through a period of remarkable growth. We will seek to fill it with gratitude for his remarkable life and work to honor him in all we do. He was 69. John C. Martin, former CEO of Gilead Sciences who helped develop the first once-a-day pill to treat HIV while at the helm of the company, died unexpectedly on March 30 after suffering head injuries from a fall the previous day. As chief executive, he and John Milligan, who would become his successor, engineered the $11 billion takeover of Pharmasset, a developer of antiviral drugs, in 2012. Gilead Sciences, Inc. (Nasdaq: GILD) today released the following statement on the death of John C. Martin, PhD, who served as the companys chief executive officer from 1996 to 2016 and as its chairman from 2008 to 2019. [7] The two companies announced that they would collaborate on the drug in 2004. But the company attracted scrutiny from health care providers and the federal government during its growth. But many of the drugs required multiple pills taken several times throughout the day. The nonprofit is based in Palo Alto. After working at Syntex Corporation, another drugmaker, from 1978 to 1984, Mr. Martin was director of antiviral chemistry at Bristol-Myers Squibb until 1990, when he joined Gilead. Gileads Viread has served as the backbone for multiple HIV treatment options. Courtesy Lou Lange. John Wayne Martin, please click here to visit our Sympathy Store. Judge rules high school math policy violates state law, Following national trend, Palo Alto looks to establish gun-free zones, City: Pagemill Pastures' use of hydrant water was 'inadvertent' and occurred just once. "We weren't making money or anything," Samuel said. Martin is believed to have fallen while walking near Coleridge Avenue and Bryant Street on March 29, said Franklin Johnson, founder of Asset Management Company and a close friend of Martin, in an email. By Alex Keown. During that time the company built a rep as a fearsome competitor in HIV, fielding drug cocktails that kept the deadly AIDS at bay for millions while also being targeted by critics for being tone deaf on pricing controversies. Its advance against hepatitis C came in 2014, with the marketing of Sovaldi, which has been said to cure 90 percent of patients with that liver virus. "[6], In 2003, Martin received the International Society for Antiviral Research's Gertrude B. Elion Award for Scientific Excellence in 2003. Time to read: about 4 minutes. Leading Gilead's success is John Martin, CEO since 1996. But he has provided a tremendous legacy for those that learned from him and a beautiful standard for us to strive toward, to measure ourselves against, and to carry forward. When I was tasked with leading Gilead Medical Affairs, I was supposed to move to the R&D building where my new boss, Norbert Bischofberger, was located. Privacy | John was an E8 in the Navy. We discussed access, pricing, and feedback on marketing messages. JOHN MARTIN OBITUARY MOUNT AIRY Mr. John Kerr Martin, age 56, of Mount Airy, passed away Monday May 12, 2014, after a long period of declining health. "If you missed doses, the HIV virus could mutate and become resistant," said Lange, who continued to work on other projects with Martin after the sale of his company. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. He read philosophy with practical aims in mind. Circulation & Delivery, About Us John.https://t.co/VF7v1jluhg, John Maraganore (@JMaraganore) March 31, 2021, John was an amazing leader, my most influential mentor and embodied a biotech success culture that fueled Gileads success. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. Before, patients receiving antiretroviral treatment could take up to 32 pills a day, said Lou Lange, a partner at Asset Management Ventures and founder of CV Therapeutics, a Palo Alto-based biotech company that was later sold to Gilead in 2009 for $1.4 billion. Samuel, who led the company's program to make the company's medicine accessible to poorer countries, credits Martin for that initiative. A truck circled Gileads headquarters in Foster City, Calif., in 2012 to protest the high cost of the companys anti-H.I.V. Martin served on the council of the National Institute of Allergy and Infectious Diseases (2000-2003). Ethel B. Wesley December 5, 2022 (91 years old) View obituary. Gileads drugs worked against the virus. According to the New York Times, the Justice Department could seek billions of dollars in royalties for Gilead's previous sales of the drug, which brings in about $3 billion each year for the company.Gilead rejected the government's complaint and has maintained that the patents were invalid. The companys HIV drugs have also been enormously successful, helping turn that disease into a more treatable, albeit chronic condition. Marjorie Eloise Rogers. Alice Bertha Anderson March 24, 1925 - February 01, 2023 Folsom, California - In loving memory of Alice B Anderson, who passed on Feb. 1, 2023 at the age of 97. He was a man of ideas. But the company attracted scrutiny from health care providers and the federal government during its growth. 1. Patients had a pill burden of more than 20 pills taken at multiple time points over the day. Sponsored content But his most notable contributions to the company came after he was named CEO in 1996. Founded in 1987, Gilead Sciences was a small pharmaceutical company with a burn rate and zero revenue, according to Clifford Samuel, the company's former senior vice president of Global Patient Solutions, who started working at the company in 1996 as a sales representative. And he continued to play an active role as a biotech investor and enthusiast backing a number of fledgling startups, including the Kronos startup led by ex-Gilead R&D chief Norbert Bischofberger, where he joined the board and the investor syndicate. Adding Tecentriq, Roches blockbuster PD-L1 antibody, to Exelixis Cabometyx did not meet the primary endpoint of progression-free survival for a group of patients with kidney cancer who have already received checkpoint therapy, Exelixis wrote in a terse update on the CONTACT-03 study. FOSTER CITY, Calif.-- ( BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) today released the following statement on the death of John C. Martin, PhD, who served as the company's chief. A couple weeks later, I gave him Hobbes Leviathan. We discussed how to best tame a growing organization and keep it from getting unwieldy and unmanageable. Leading Gilead's success is John Martin, CEO since 1996. Individual Subscription Home & Real Estate Place a Legal Notice He didnt make the cover of magazines, even when he led the company that did more than any other to transform HIV into a chronic, manageable disease. Express / Weekend Express "We developed the drug; we invented it. A cause of death has not been announced. John H. Clark, age 94 of Mount Gilead died on Friday, December 9, 2022, at the Woodside Village Care Center. . John C. Martin, 69, Dies; Led Drugmaker in Breakthroughs, https://www.nytimes.com/2021/04/27/business/john-c-martin-69-dies-led-drugmaker-in-breakthroughs.html. John C. Martin, former CEO of Gilead Sciences who helped develop the first once-a-day pill to treat HIV while at the helm of the company, died unexpectedly on March 30 after suffering head injuries from a fall the previous day. drugs. He let other executives do the talking for Gilead. His dedication to the vision of Gilead and getting quality products to the patients that needed them was an inspiration to all of us who worked for him. In 2014, Democrat lawmakers asked Martin to justify the company's $84,000 price tag of its hepatitis C drug, Sovaldi, which is equivalent to $1,000 per pill. Get In-depth Biotech Coverage with Timmerman Report. But the company attracted scrutiny from health care providers and the federal government during its growth.
John Martin MBA 84, LHD 03 Former Executive Chairman at Gilead Sciences Making a Mark with Anti-Virals Under the visionary leadership of President and CEO John Martin, Gilead Sciences produced its first profit in 2002 earned both sales of $3 billion and the number three spot of distinction on the Business Week Select 50 only five years later. Print Edition/Archives Add Photos. Martin earned a bachelor's degree in chemical engineering from Purdue University,[2] an MBA in marketing from Golden Gate University and a PhD in organic chemistry from the University of Chicago. Johns legacy will be felt for generations to come, living on through the scientific progress made under his leadership and the programs he championed that expanded access to medications for people around the world, said Daniel ODay, Chairman and Chief Executive Officer, Gilead Sciences. He was on the Presidential Advisory Council on HIV/AIDS (2006-2009). Martin oversaw a period of growth in the company when Gilead essentially created a cure for hepatitis C, which generated an enormous revenue stream for the company with its powerhouse drugs, Harvoni and Sovaldi. [20], Last edited on 17 February 2023, at 00:55, Pandemic Perspectives with John C. Martin, President's Emergency Plan for AIDS Relief, International Society for Antiviral Research, National Institute of Allergy and Infectious Diseases, Centers for Disease Control and Prevention, Presidential Advisory Council on HIV/AIDS, "Gilead's John C. Martin: One Breakthrough Drug After Another", "John Martin: Executive Profile & Biography - Businessweek", "FDA Approves Gilead, Bristol-Myers Squibb Once-a-Day Combination Antiretroviral Pill", "Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate) Tablets", "HIV/AIDS Historical Time Line 2000 - 2010", "Gilead's John Martin scores 'best CEO' trophy for huge stock gains", "Gilead's $84,000 Treatment Questioned by U.S. The pill combined two of the most prescribed AIDS medications at the time Gilead's Truvada and Bristol-Myers Squibb's Sustiva and was set at a price of $1,100 a month.Before, patients receiving antiretroviral treatment could take up to 32 pills a day, said Lou Lange, a partner at Asset Management Ventures and founder of CV Therapeutics, a Palo Alto-based biotech company that was later sold to Gilead in 2009 for $1.4 billion. His tenure in the pharmaceutical industry spanned at least four decades. John Palmer Martin February 10, 1947 - September 30, 2021 As resident of Petaluma, Ca since 1974, John was continually involved in community projects. John loved to work. John C. Martin, who led Gilead to greatness in developing a hugely profitable HIV drug franchise, has died. - Click to learn more.. John set the example himself. Martin also started a foundation under his name with a mission to improve health care in "socially and economically-disadvantaged settings," according to the foundation's website. A&E [13], Martin was president of the International Society for Antiviral Research (1998-2000); chairman of the California Healthcare Institute (2005-2006, 2009); and chairman of BayBio (1999-2001). The critics were relentless and vocal. A memorial service will be held at a later date. These performance metrics led Harvard Business Review in 2010 to rank Martin #6 in their first edition of Best Performing CEOs in the World (Steve Jobs was #1). He was 70 years old. The man was transported to a nearby hospital where he later died. He was a resident of Old Palo Alto. A few years later, Martin moved up to #2 behind Amazons Jeff Bezos. Terms of Use Make a life-giving gesture Become a member today. [4][1] Gilead is known for developing drugs such as Atripla (for HIV/AIDS) and commercializing Sovaldi (sofosbuvir) for the treatment of the liver virus hepatitis C. Martin is the recipient of a number of awards, including the Biotechnology Heritage Award (2017). John C. Martin, former CEO of Gilead Sciences who helped develop the first once-a-day pill to treat HIV while at the helm of the company, died unexpectedly on March 30 after suffering head injuries from a fall the previous day. Martin, who had a background in chemical engineering and organic chemistry and had done a brief stint at Bristol-Myers Squibb, joined Gilead in 1990 with the pioneering idea that nucleotides could be used as an effective drug for HIV treatment. He will be greatly missed. Founded in 1987, Gilead Sciences was a small pharmaceutical company with a burn rate and zero revenue, according to Clifford Samuel, the company's former senior vice president of Global Patient Solutions, who started working at the company in 1996 as a sales representative. The delivery challenges and high cost of goods meant it would probably take 20 years for these therapies to pan out, he reasoned. "He was a visionary that really understood medical science, drug development and could take the straightest path to success," Lange said. Local obituaries for Mount Gilead, North Carolina 128 Results Thursday, February 23, 2023 Add Photos Add a Memory Alge Metcalf Jr. Alge Metcalf's passing at the age of 88 on Monday, February. A quarters-long flurry of layoffs has caused thousands of workers in life sciences to go hunting for their next position sooner than expected, and the latest wave could make it more difficult to get new offers in hand in short order.